Vaccine safety

Vaccines

Volumn , Issue , 2008, Pages 1629-1650

  Offit, Paul A ^a,b   Davis, Robert L ^c   Gust, Deborah ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85158919953     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50078-7     Document Type: Chapter

References (376)

1. JP Bunker, HS Frazier and F Mosteller (1994) Improving health: measuring effects of medical care. Milbank Quarterly 72 225-258.
2. H Udawat, HR Chaudhary, RK Goyal, et al. (2001) Guillain-Barré syndrome following antirabies Semple vaccine-a report of six cases. Assoc Physicians India 49 384-385.
3. RS Javier, T Kunishita, R Koike and T Tabira (1989) Semple rabies vaccine: presence of myelin basic protein and proteolipid protein and its activity in experimental allergic encephalomyelitis. J Neurol Sci 93 221-230.
4. D Laouini, MF Kennou, S Khoufi and K Dellagi (1998) Antibodies to human myelin proteins and gangliosides in patients with acute neuroparalytic accidents induced by brain-derived rabies vaccine. Neuroimmunol 91 63-72.
5. F Bahri, A Letaief, M Ernez, et al. (1996) Neurological complications in adults following rabies vaccine prepared from animal brains. Presse Med 25 491-493.
6. JP Fox, C Manso, HA Penna and M Para (1942) Observations on the occurrence of icterus in Brazil following vaccination against yellow fever. Am J Hygiene 36 68-116.
7. MV Hargett and HW Burruss (1943) Aqueous-base yellow fever vaccine. Pub Health Reports 58 505-512.
8. WA Sawyer, KF Meyer, MD Eaton, et al. (1944) Jaundice in army personnel in the western region of the United States and its relation to vaccination against yellow fever. Am J Hygiene 40 35-107.
9. LB Seeff, GW Beebe, JH Hoofnagle, et al. (1987) A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 316 965-970.
10. PA Offit (2005) The Cutter Incident: How America's first polio vaccine led to the growing vaccine crisis New Haven and London: Yale University Press
11. CP Howson, CJ Howe and HV Fineberg (Eds) (1991) Adverse Effects of Pertussis and Rubella Vaccines: A Report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines Washington, DC: National Academy Press
12. D Miller, J Wadsworth, J Diamond, et al. (1985) Pertussis vaccine and whooping cough as risk factors in acute neurological illness and death in young children. Dev Biol Stand 61 389-394.
13. H Peltola and OP Heinonen (1986) Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind placebo controlled trial in twins. Lancet 1 939-942.
14. M Virtanen, H Peltola, M Paunio and OP Heinonen (2000) Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 106 e62.
15. S Edees, CR Pullan and D Hull (1991) A randomized single blind trial of a combined measles-mumps-rubella vaccine to evaluate serological response and reactions in the UK population. Public Health 105 91-97.
16. T Shohat, MS Green, O Nakar, et al. (2000) Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Ist Med Assoc J 2 192-195.
17. CP Howson, CJ Howe and HV Fineberg (1991) Chronic arthritis. Adverse Effects of Pertussis and Rubella Vaccines Washington, DC: National Academy Press 196.
18. RA Oski and JL Naiman (1966) Effect of live measles vaccine on the platelet count. N Engl J Med 275 352-356.
19. Institute of Medicine (1994) Measles and mumps vaccine. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality Washington, DC: National Academy Press 130.
20. LB Schonberger, DJ Bregman, JZ Sullivan-Bolyai, et al. (1979) Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 110 105-123.
21. Centers for Disease Control and Prevention (1997) Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 46 1-25.
22. CW Bierman, GG Shapiro, WE Pierson, et al. (1977) Safety of influenza vaccination in allergic children. J Infect Dis 136 S652-S655.
23. JM James, RS Zieger, MR Lester, et al. (1998) Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 133 624-628.
24. JM Kelso, RT Jones and JW Yunginger (1993) Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol 91 867-872.
25. GS Wilson (1967) The Hazards of Immunization London: Athlone Press
26. MD McGoldrick and GR Bailie (1997) Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities. Ann Pharmacother 31 221-227.
27. DR Nalin (2002) Evidence based vaccinology. Vaccine 20 1624-1630.
28. M Mathieu (Eds) (1993) A Regulatory Overview Waltham, MA: Paraxel Biologic Development
29. F Verdier (2002) Non-clinical vaccine safety assessment. Toxicology 174 37-43.
30. MD Decker, KM Edwards, MC Steinhoff, et al. (1995) Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 96 557-566.
31. KL Rosenthal and LD McVittie (1993) The clinical testing of preventive vaccines. M Mathieu (Eds) Biologic Development: A Regulatory Overview Waltham, MA: Paraxel 119-130.
32. ME Pichichero (1996) Acellular pertussis vaccine: towards an improved safety profile. Drug Experience 15 311-324.
33. RT Chen (2000) Special methodological issues in pharmacoepidemiology studies of vaccine safety. BL Strom (Eds) Pharmacoepidemiology Sussex, UK: John Wiley 707-722.
34. J Bonhoeffer, K Kohl, R Chen, et al. (2002) The Brighton collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 21 298-302.
35. F Brown, D Greco, P Mastantonio, et al. (1997) Pertussis vaccine trials. Dev Biol Stand 89 1-410.
36. RT Chen (1997) Safety of acellular pertussis vaccine: follow-up studies. Dev Biol Stand 89 373-375.
37. H Heijbel, MC Ciofi degli Atti, E Harzer, et al. (1997) Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Dev Biol Stand 89 101-103.
38. RM Jacobson, A Adegbenro, VS Pankratz, et al. (2001) Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. Vaccine 19 2428-2433.
39. GM Ruiz-Palacios, I Perez-Schael, FR Velazquez, et al. (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 11-22.
40. T Vesikari, DO Matson, P Dennehy, et al. (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 23-33.
41. SA Plotkin (2001) Lessons learned concerning vaccine safety. Vaccine 20(Suppl 1), S16-S19.
42. RL Davis, M Kolczek, E Lewis, et al. (2005) Active surveillance of vaccine safety data for early signal detection. Epidemiol 16 336-341.
43. TF Scott and DE Bonanno (1967) Reactions to live-measles-virus vaccine in children previously inoculated with killed-virus vaccine. N Engl J Med 277 248-250.
44. JV Bennett, FT Cutts and SL Katz (1999) Edmonston-Zagreb measles vaccine: a good vaccine with an image problem. Pediatrics 104 1123-1124.
45. RT Chen (2000) Special methodological issues in pharmacoepidemiology studies of vaccine safety. BL Strom (Eds) Pharmacoepidemiology Sussex, UK: John Wiley 707-722.
46. MC Steinhoff, GF Reed, MD Decker, et al. (1995) A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics 96 567-570.
47. LJ Baraff, CL Cody and JD Cherry (1984) DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 73 31-36.
48. LJ Baraff, CR Manclark, JD Cherry, et al. (1989) Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J 8 502-507.
49. Chen RT. Evaluation of vaccine safety post-9/11: role of cohort and case-control studies. Vaccine [in press].
50. CP Farrington, J Nash and E Miller (1996) Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 143 1165-1173.
51. DL Kennedy, SA Goldman and RB Lillie (2000) Spontaneous reporting in the U.S. BL Strom (Eds) Pharmacoepidemiology Sussex, UK: John Wiley 151-174.
52. KG Alberti (2001) Medical errors: a common problem. BMJ 322 501-502.
53. BE Wiholm, S Olsoon and N Moore (2000) Spontaneous reporting systems outside the U.S. BL Strom (Eds) Pharmacoepidemiology Sussex, UK: John Wiley 175-192.
54. AP Jonville-Bera, E Autret, C Galy-Eyraud, et al. (1996) Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and Pasteur-Merieux Serums et Vaccins. Pediatr Infect Dis J 15 44-48.
55. H Takahashi (2000) Need for improved vaccine safety surveillance. Vaccine 19 1004.
56. O Mansoor and PI Pillans (1997) Vaccine adverse events reported in New Zealand 1990–5. N Z Med J 110 270-272.
57. J Taranger and K Holmberg (1992) Urgent to introduce countrywide and systematic evaluation of vaccine side effects. Lakartidningen 89 1691-1693.
58. DM Salisbury and NT Beggs (Eds) (1996) 1996 Immunisation Against Infectious Disease London: Her Majesty's Stationery Office 29-33.
59. Anonymous (1995) Surveillance of serious adverse events following vaccination. Commun Dis Intell (Aust) 19 273-274.
60. P Duclos (1994) Surveillance of secondary effects of vaccination [in French]. Sante 4 215-220.
61. P Duclos, J Hockin, R Pless and B Lawler (1997) Reporting vaccine-associated adverse events. Can Fam Physician 43 1551-1556. 1559–1560
62. BM Galindo Santana, S.M.A. Galindo Sardina MA and RA Perez (1999) Adverse reaction surveillance system for vaccination in the Republic of Cuba [in Spanish]. Rev Cubana Med Trop 51 194-200.
63. MM Andersen and T Ronne (1991) Side-effects with Japanese encephalitis vaccine. Lancet 337 1044.
64. J Sokhey (1991) Adverse events following immunization: 1990. Indian Pediatr 28 593-607.
65. S Squarcione and L Vellucci (1996) Adverse reactions following immunization in Italy in the years 1991–93. Ig Mod 105 1419-1431.
66. R Fescharek, C Arras-Reiter, ER Arens, et al. (1997) Oral vaccines against poliomyelitis and vaccination-related paralytic poliomyelitis in Germany. Do we need a new immunization strategy. [in German] Wien Med Wochenschr 147(19–20), 456-461.
67. SC Rastogi (Eds) (1993) International Workshop: Harmonization of Reporting of Adverse Events Following Vaccination Rockville, MD: Center for Biologics Evaluation and Research
68. Vermeer-de Bondt PE, Wesselo C, Dzaferagic A, et al. Adverse events following immunisation under the national vaccination programme of the Netherlands. Part VII-reports in 2000. Bilthoven, RIVM, 000001006, 2002.
69. GS Brito (1991) System of Investigation and Notification of Adverse Events Following Immunization: Preliminary Report Sao Paolo: State of Sao Paolo, Brazil, Health Department
70. RT Chen, SC Rastogi, JR Mullen, et al. (1994) The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12 542-550.
71. Centers for Disease Control and Prevention (1988) National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination. MMWR Morb Mortal Wkly Rep 37 197-200.
72. HC Stetler, JR Mullen, JP Brennan, et al. (1987) Monitoring system for adverse events following immunization. Vaccine 5 169-174.
73. Food and Drug Administration (1989) COSTART-Coding Symbols for Thesaurus of Adverse Reaction Terms, 3rd ed Rockville, MD: Food and Drug Administration
74. Division of Immunization (1995) Vaccine-associated adverse events in Canada, 1992 Report. Can Commun Dis Rep 21 117-128.
75. R Morris (1993) Halperin S, Dery P, et al. IMPACT monitoring network: a better mousetrap. Can J Infect Dis 4 194-195.
76. JP Collet, N MacDonald, N Cashman, et al. (2000) Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Advisory Committee on Causality Assessment. Bull World Health Organ 78 178-185.
77. M Lindquist and IR Edwards (2001) The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol 28 1180-1187.
78. Food and Drug Administration (1997) International Conference on Harmonisation: Guideline on clinical safety data management: periodic safety update reports for marketed drugs. Fed Reg 62 27470-27476.
79. HF Retailliau, AC Curtis, G Storr, et al. (1980) Illness after influenza vaccination reported through a nationwide surveillance system, 1976–1977. Am J Epidemiol 111 270-278.
80. LR Zanardi, P Haber, GT Mootrey, et al. (2001) Intussusception among recipients of rotavirus vaccine: reports to the Vaccine Adverse Event Reporting System. Pediatrics 107 E97.
81. TV Murphy, PM Gargiullo, MS Massoudi, et al. (2001) Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 564-572.
82. P Kramarz, EK France, F DeStefano, et al. (2001) Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 20 410-416.
83. G Peter and MG Myers (2002) Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 110(6), e67.
84. Centers for Disease Control and Prevention (2002) Yellow fever vaccine: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR 51(RR-17),
85. M Martin, TF Tsai, B Cropp, et al. (2001) Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 98-104.
86. M Martin, LH Weld, TF Tsai, et al. (2001) Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 7 945-951.
87. RC Chan, DJ Penney, D Little, et al. (2001) Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358 121-122.
88. AM Walker (2001) Pattern recognition in health insurance claims databases. Pharmacoepidemiol Drug Saf 10 393-397.
89. SS Ellenberg and RT Chen (1997) The complicated task of monitoring vaccine safety. Public Health Rep 112 10-20.
90. Centers for Disease Control and Prevention (2003) Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991–2001. MMWR 52(SS-1),
91. JC Lloyd, JA Singleton, GJ Terracciano, et al. (1996) Evaluation of a surveillance system: Vaccine Adverse Event Reporting System [abstract]. Pharmacoepidemiol Drug Saf 5(Suppl), S44.
92. RP Wise, KP Kiminyo and ME Salive (1997) Hair loss after routine immunizations. JAMA 278 1176-1178.
93. J Beeler, F Varricchio and R Wise (1996) Thrombocytopenia after immunization with measles vaccines: review of the Vaccine Adverse Events Reporting System (1990 to 1994). Pediatr Infect Dis J 15 88-90.
94. R Weibel, JW Glasser and RT Chen (1997) Encephalopathy after measles vaccination: accumulative evidence from four independent surveillance systems [abstract]. Pharmacoepidemiol Drug Saf 6(Suppl), S60.
95. MM Braun, PA Patriarca and SS Ellenberg (1997) Syncope after immunization. Arch Pediatr Adolesc Med 151 255-259.
96. S Rosenthal, R Chen and S Hadler (1996) The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine: a postmarketing assessment. Arch Pediatr Adolesc Med 150 457-460.
97. S Rosenthal and R Chen (1995) The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 85 1706-1709.
98. T Verstraeten, AL Baughman, B Cadwell, et al. (2001) Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. Am J Epidemiol 154 1006-1012.
99. RT Chen, JH Kent, PH Rhodes, et al. (1992) Investigation of a possible association between influenza vaccination and Guillain-Barre syndrome in the United States, 1990–1991 [abstract]. Postmarketing Surveill 6 5-6.
100. DJ Finney (1982) The detection of adverse reactions to therapeutic drugs. Stat Med 1 153-161.
101. BL Strom and JL Carson (1990) Use of automated databases for pharmacoepidemiology research. Epidemiol Rev 12 87-107.
102. P Farrington, S Pugh, A Colville, et al. (1995) A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345 567-569.
103. JC Lloyd and RT Chen (1996) The Urabe mumps vaccine: lessons in adverse event surveillance and response [abstract]. Pharmacoepidemiol Drug Saf 5(Suppl), S45.
104. T Lasky, GJ Terracciano, L Magder, et al. (1997) Association of the Guillain-Barre syndrome with the 1992–93 and 1993–94 influenza vaccines [abstract]. Am J Epidemiol 145(Suppl), S57.
105. MT Niu, P Rhodes, M Salive, et al. (1998) Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 51 503-510.
106. MJ Goodman and J Nordin (2006) Vaccine adverse event reporting source: a possible source of bias in longitudinal studies. Pediatrics 117 387-390.
107. PA Patriarca, F Laender, G Palmeira, et al. (1988) Randomised trial of alternative formulations of oral poliovaccine in Brazil. Lancet 1 429-433.
108. I Bhargava, BC Chhaparwal, MA Phadke, et al. (1996) Reactogenicity of indigenously produced measles vaccine. Indian Pediatr 33 827-831.
109. WA Orenstein, L Markowitz, SR Preblud, et al. (1986) Appropriate age for measles vaccination in the United States. Dev Biol Stand 65 13-21.
110. R Booy, SJ Aitken, S Taylor, et al. (1992) Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 339 507-510.
111. A Deforest, SS Long, HW Lischner, et al. (1988) Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 81 237-246.
112. D Scheifele, B Law, L Mitchell, et al. (1996) Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine 14 1399-1406.
113. P Aaby, B Samb, F Simondon, et al. (1996) A comparison of vaccine efficacy and mortality during routine use of high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in rural Senegal. Trans R Soc Trop Med Hyg 90 326-330.
114. Expanded Programme on Immunization (EPI). Safety of high titer measles vaccines. Wkly Epidemiol Rec 67 357-361.
115. W Meekison, M Hutcheon, R Guasparini, et al. (1989) Post-marketing surveillance of adverse events following PROHIBIT vaccine in British Columbia. Can Med Assoc J 141 927-929.
116. SB Black and HR Shinefield (1987) b-CAPSA I Haemophilus influenzae, type b, capsular polysaccharide vaccine safety. Pediatrics 79 321-325.
117. CM Vadheim, DP Greenberg, SM Marcy, et al. (1990) Safety evaluation of PRP-D Haemophilus influenzae type b conjugate vaccine in children immunized at 18 months of age and older: follow-up study of 30,000 children. Pediatr Infect Dis J 9 555-561.
118. Centers for Disease Control and Prevention (1996) Unintentional administration of varicella virus vaccine-United States, 1996. MMWR Morb Mortal Wkly Rep 45 1017-1018.
119. P Coplan, S Black, HA Guess, et al. (1997) Post-marketing safety of varicella vaccine among 44,369 vaccinees [abstract]. Am J Epidemiol 145(Suppl), S76.
120. Centers for Disease Control and Prevention (1993) Inactivated Japanese encephalitis virus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 42 1-15.
121. N Nathanson and AD Langmuir (1963) The Cutter incident. Am J Hyg 78 16-18.
122. DA Henderson, JJ Witte, L Morris, et al. (1964) Paralytic disease associated with oral polio vaccines. JAMA 190 153-160.
123. RH Bernier, JA Frank Jr, TJ Dondero Jr, et al. (1982) Diphtheria-tetanus toxoids-pertussis vaccination and sudden infant deaths in Tennessee. J Pediatr 101 419-421.
124. LK Solberg (1985) DTP Vaccination, Visit to Child Health Center and Sudden Infant Death Syndrome (SIDS): Evaluation of DTP Vaccination. Report to the Oslo Health Council 1985 Bethesda, MD: NIH Library Translation 85-152.
125. MH Bouvier-Colle, A Flahaut, A Messiah, et al. (1989) Sudden infant death and immunization: an extensive epidemiological approach to the problem in France-winter 1986. Int J Epidemiol 18 121-126.
126. EA Mitchell, AW Stewart and M Clements (1995) Immunisation and the sudden infant death syndrome. New Zealand Cot Death Study Group. Arch Dis Child 73 498-501.
127. R Alderslade, MH Bellman, NSB Rawson, et al. (1981) The National Childhood Encephalopathy Study. Whooping Cough: Reports from the Committee on the Safety of Medicines and the Joint Committee on Vaccination and Immunisation, Department of Health and Social Security London: HM Stationary Office 79-169.
128. JL Gale, PB Thapa, SG Wassilak, et al. (1994) Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine: a population-based case-control study. JAMA 271 37-41.
129. M Kimura, H Kuno-Sakai, S Yamazaki, et al. (1996) Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn 38 205-211.
130. PA Simon, RT Chen, JA Elliott, et al. (1993) Outbreak of pyogenic abscesses after diphtheria and tetanus toxoids and pertussis vaccination. Pediatr Infect Dis J 12 368-371.
131. KR Stratton, CJ Howe and RB Johnston (Eds) (1994) Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality Washington, DC: National Academy Press
132. RT Chen, JW Glasser, PH Rhodes, et al. (1997) Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 99 765-773.
133. JD Roberts, LL Roos, LA Poffenroth, et al. (1996) Surveillance of vaccine-related adverse events in the first year of life: a Manitoba cohort study. J Clin Eqidemiol 49 51-58.
134. T Verstraeten, F DeStefano, RT Chen, et al. (2003) Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guide. Expert Rev Vaccines 2 21-29.
135. RT Chen, F De Stefano, RL Davis, et al. (2000) The Vaccine safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 78 186-194.
136. AM Walker, H Jick, DR Perera, et al. (1987) Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health 77 945-951.
137. MR Griffin, WA Ray, EA Mortimer, et al. (1990) Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA 263 1641-1645.
138. RL Davis, E Marcuse, S Black, et al. (1997) MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 100 767-771.
139. JC Williams, KL Goldenthal, DL Burns and BP Lewis Jr (Eds) (1995) Combined Vaccines and Simultaneous Administration: Current Issues and Perspective New York: New York Academy of Science
140. MR Griffin, WA Ray, JR Livengood, et al. (1988) Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N Engl J Med 319 618-623.
141. PE Fine and RT Chen (1992) Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 136 121-135.
142. KJ Rothman (Eds) (1988) Causal Inference Chestnut Hill, MA: Epidemiology Resources
143. Zanoni G, Dung NTM, Tridente G. Fourth report on the Green Channel activities and the monitoring system of reactions to vaccines in the Veneto Region: Analysis of the three year period 1997–1999, General summary 1992–1999. Immunology Section, University of Verona, Italy; 2000. Italian.
144. H Goodwin, M Nash, M Gold, et al. (1999) Vaccination of children following a previous hypotonic-hyporesponsive episode. J Paediatr Child Health 35 549-552.
145. MS Gold (2002) Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern? Drug Saf 25 85-90.
146. KA Phillips, DL Veenstra, E Oren, et al. (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286 2270-2279.
147. PR Paradiso (2001) Maternal immunization: the influence of liability issues on vaccine development. Vaccine 20(Suppl 1), S73-S74.
148. M Kulenkampff, JS Schwartzman and J Wilson (1974) Neurological complications of pertussis inoculation. Arch Dis Child 49 46-49.
149. EJ Gangarosa, AM Galazka, CR Wolfe, et al. (1998) Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 351 356-361.
150. CL Cody, LJ Baraff, JD Cherry, et al. (1981) Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 68 650-660.
151. TM Pollock and J Morris (1983) A 7-year survey of disorders attributed to vaccination in Northwest. Thames Region. Lancet 1 753-757.
152. AM Walker, H Jick, DR Perera, et al. (1988) Neurologic events following diphtheria-tetanus-pertussis immunization. Pediatrics 81 345-349.
153. MR Griffin, WA Ray, W Schaffner, et al. (1990) Risk of seizures and encephalopathy after immunization with diphtheria-tetanus-pertussis vaccine. JAMA 263 1641-1645.
154. WD Shields, C Nielsen, D Buch, et al. (1988) Relationship of pertussis immunization to the onset of neurologic disorders. J Pediatr 113 801-805.
155. JL Gale, PB Thapa, SGF Wassilak, et al. (1994) Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine: a population-based case-control study. JAMA 271 37-41.
156. GS Golden (1990) Pertussis vaccine and injury to the brain. J Pediatr 116 854-861.
157. KL Tyler (2000) Prions and prion diseases of the central nervous system (transmissible neurodegenerative diseases). GL Mandell, JE Bennett, RE Dolin (Eds) Principles and Practice of Infectious Diseases 5th ed London: Churchill Livingstone 1971-1985.
158. Curtis T. The Origin of AIDS: A Startling New Theory Attempts to Answer the Question ‘Was It an Act of God or an Act of Man?,’ Rolling Stone Magazine, March 19, 1992.
159. E Hooper (1999) The River A Journey to the Source of HIV and AIDS Boston: Little, Brown
160. SA Plotkin (2004) Chimpanzees and journalists. Vaccine 22 1829-1830.
161. SA Plotkin, DE Teuwen, A Prinzie and J Desmyter (2001) Postscript relating to new allegations made by Edward Hooper at The Royal Society Discussion Meeting on 11 September 2000. Phil Trans Royal Soc London 356 825-829.
162. SA Plotkin (2001) Untruths and consequences: the false hypothesis linking CHAT type 1 polio vaccination to the origin of human immunodeficiency virus. Phil Trans Royal Soc London 356 815-823.
163. SA Plotkin and H Koprwoski (2000) No evidence to link polio vaccine with HIV. Nature 407 941.
164. KV Shah (2004) Simian virus 40 and human disease. J Infect Dis 190 2061-2064.
165. BG Gellin, EW Maibach and EK Marcuse (2000) Do parents understand immunizations? A national telephone survey. Pediatrics 106 1097-1102.
166. M Cohn and RE Langman (1990) The Protecton: the unit of humoral immunity selected by evolution. Immunol Rev 115 11-147.
167. A Arvin and A Gershon (1996) Live attenuated varicella vaccine. Annu Rev Microbiol 50 59-100.
168. F Averhoff, F Mahoney, P Coleman, et al. (1998) Risk factors for lack of response to hepatitis B vaccines: a randomized trial comparing the immunogenicity of recombinant hepatitis B vaccines in an adult population. Am J Prev Med 15 1-8.
169. DD Ho, AU Neumann, AS Perelson, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 123-126.
170. CA Siegrist (2001) Neonatal and early life vaccinology. Vaccine 19 3331-3346.
171. L Mellander, B Carlsson, E Jalil, et al. (1985) Secretory IgA antibody response against Escherichia coli antigens in infants in relation to exposure. J Pediatr 107 430-433.
172. SM Wheely, PT Jackson, EH Boxhall, et al. (1991) Prevention of perinatal transmission of hepatitis B virus (HBV): a comparison of two prophylactic schedules. J Med Virol 35 212-215.
173. VC Wong, HM Ip, HW Reesink, et al. (1984) Prevention of the HBsAg carrier state in newborns of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin: double-blind randomized placebo-controlled study. Lancet 28 921-926.
174. OW Prozesky, CE Stevens, W Szmunes, et al. (1983) Immune response to hepatitis B vaccine in newborns. J Infect 7(Suppl I), S53-S55.
175. A Clark and P Rudd (1992) Neonatal BCG immunization. Arch Dis Child 67 473-474.
176. A Marchant, T Gretghebuer, MO Ota, et al. (1999) Newborns develop a TH1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol 163 2249-2255.
177. GA Colditz, TF Brewe, CS Berkey, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271 698-702.
178. SA Plotkin and WA Orenstein (Eds) (2003) Vaccines 4th ed Philadelphia: WB Saunders
179. P Anderson, DL Ingram, M Pichichero and G Peter (2000) A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr Infect Dis J 19 589-591.
180. G Lesinski and M Westerink (2001) Novel vaccine strategies to T-independent antigens. J Microbiol Methods 47 135-149.
181. C Karp (1999) Measles, immunosuppression, interleukin-12 and complement receptors. Immunol Rev 168 91-101.
182. C Karp, M Wysocka, L Wahl, et al. (1996) Mechanism of suppression of cell-mediated immunity by measles virus. Science 273 228-231.
183. KB Laupland, HD Davies, DE Low, et al. (2000) Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics 105 E60.
184. KL O'Brien, MI Walters, J Sellman, et al. (2000) Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 30 784-789.
185. JA Brody and R McAlister (1964) Depression of tuberculin sensitivity following measles vaccination. Am Rev Resp Dis 90 607-611.
186. R Ganguly, CL Cusumano and RH Waldman (1976) Suppression of cell-mediated immunity after infection with attenuated rubella virus. Infect Immun 13 464-469.
187. S Starr and S Berkovich (1964) Effects of measles, gamma-globulin-modified measles and vaccine measles on the tuberculin test. N Engl J Med 270 386-391.
188. JA Brody, T Overfield and LM Hammes (1964) Depression of the tuberculin reaction by viral vaccines. N Engl J Med 271 1294-1296.
189. T Kupers, JM Petrich, AW Holloway and JW Geme St (1970) Depression of tuberculin delayed hypersensitivity by live attenuated mumps virus. J Pediatr 76 716-721.
190. B Zweiman, D Pappagianis, H Maibach and EA Hildreth (1971) Effect of measles immunization on tuberculin hypersensitivity and in vitro lymphocyte reactivity. Int Arch Allergy 40 834-841.
191. RL Hirsch, F Mokhtarian, DE Griffin, et al. (1981) Measles virus vaccination of measles seropositive individuals suppresses lymphocyte proliferation and chemotactic factor production. Clin Immunol Immunopathol 21 341-350.
192. Centers for Disease Control and Prevention (2001) Simultaneous administration of varicella vaccine and other recommended childhood vaccines-United States, 1995–1999. MMWR 50 1058-1061.
193. N Halsey (1993) Increased mortality after high-titer measles vaccines: too much of a good thing. Pediatr Infect Dis J 12 462-465.
194. SB Black, JD Cherry, HR Shinefield, et al. (1991) Apparent decreased risk of invasive bacterial disease after heterologous childhood immunization. Am J Dis Child 145 746-749.
195. M Davidson, W Letson, JI Ward, et al. (1991) DTP immunization and susceptibility to infectious diseases: is there a relationship? Am J Dis Child 145 750-754.
196. J Storsaeter, P Olin, B Renemar, et al. (1988) Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect Dis J 7 637-645.
197. S Otto, B Mahner, I Kadow, et al. (2000) General non-specific morbidity is reduced after vaccination within the third month of life-the Greifswald study. J Infect 41 172-175.
198. A Hviid, J Wohlfahrt, M Stellfeld and M Melbye (2005) Childhood vaccination and nontargeted infectious disease hospitalization. JAMA 294 699-705.
199. CA Janeway and P Travers (1997) Immunobiology: the Immune System in Health and Disease 2nd ed. New York: Garland
200. T Kamradt and N Mitchison (2001) Tolerance and autoimmunity. N Engl J Med 344 655-664.
201. I Mackay (2000) Science, medicine, and the future: tolerance and autoimmunity. BMJ 321 93-96.
202. H Jonuleit, E Schmitt, K Steinbrink and A Enk (2001) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 22 394-400.
203. K Maloy and F Powrie (2001) Regulatory T cells in the control of immune pathology. Nat Immunol 2 816-822.
204. S Sharif, GA Arreaza, P Zucker, et al. (2001) Activation of natural killer cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 7 1057-1062.
205. E Shevach (2001) Certified professionals: CD4+CD25+ suppressor T cells. J Exp Med 193 F41-F46.
206. L Blom, L Nystrom and G Dahlquist (1991) The Swedish childhood diabetes study: vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia 34 176-181.
207. ME Parent, J Siemiatycki, R Menzies, et al. (1997) Bacille Calmette-Guerin vaccination and incidence of IDDM in Montreal, Canada. Diabetes Care 20 767-772.
208. F DeStefano, JP Mullooly, CA Okoro, et al. (2001) Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 108 E112.
209. Childhood immunizations and type 1 diabetes: summary of an Institute for Vaccine Safety Workshop. The Institute for Vaccine Safety Diabetes Workshop Panel. Pediatr Infect Dis J 18 217-222.
210. T Jefferson and V Demicheli (1998) No evidence that vaccines cause insulin dependent diabetes mellitus. J Epidemiol Community Health 52 674-675.
211. A Fourrier, E Touze, A Alperovitch and B Begaud (1999) Association between hepatitis B vaccine and multiple sclerosis: a case-control study. Pharmacoepidemiol Drug Saf 8(Suppl), S140-S141.
212. MCJM Sturkenboom, L Abenhaim, C Wolfson, et al. (1999) Vaccinations, demyelination, and multiple sclerosis study (VDAMS): a population-based study in the UK. Pharmacoepidemiol Drug Saf 8(Suppl), S170-S171.
213. E Touze, O Gout, MH Verdier-Taillefer, et al. (2000) Premier episode de demyelinisation du systeme nerveux central et vaccination contre l'hepatite B: etude cas-temoins pilote. Rev Neurol (Paris) 156 242-246.
214. A Hall, M Kane, C Roure and A Meheus (1999) Multiple sclerosis and hepatitis B vaccine? Vaccine 17 2473-2475.
215. A Ascherio, SM Zhang, MA Hernan, et al. (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344 327-332.
216. C Confavreux, S Suissa, P Saddier, et al. (2001) Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 344 319-326.
217. NF Moriabadi, S Niewiesk, N Kruse, et al. (2001) Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56 938-943.
218. AE Miller, LA Morgante, LY Buchwald, et al. (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48 312-314.
219. J De Keyser, C Zwanikken and M Boon (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sciences 159 51-53.
220. GJ Fournie, M Mas, B Cautain, et al. (2001) Induction of autoimmunity through bystander effects: lessons from immunologic disorders induced by heavy metals. J Autoimmun 16 319-326.
221. D Strachan (2000) Family size, infection, and atopy: the first decade of the ‘hygiene hypothesis.’. Thorax 55(Suppl 1), S2-S10.
222. M Wills-Karp, J Santeliz and C Karp (2001) The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 1 69-75.
223. R Flavell, C Dong and R Davis (2002) Signaling and cell death in lymphocytes. Inflamm Res 51 80-82.
224. JM Brewer, M Conacher, CA Hunter, et al. (1999) Aluminum hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 163 6448-6454.
225. M Ulanova, A Tarkowski, M Hahn-Zoric and L Hanson (2001) The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin 4-dependent mechanism. Infect Immun 69 1151-1159.
226. C Gruber, L Nilsson and B Bjorksten (2001) Do early childhood immunizations influence the development of atopy and do they cause allergic reactions? Pediatr Allergy Immunol 12 296-311.
227. X Wang and T Mosmann (2001) In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma and can subsequently differentiate into IL-4- or IFN-gamma secreting cells. J Exp Med 194 1069-1080.
228. H Kobayashi, AA Horner, K Takabayashi, et al. (1999) Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell Immunol 198 69-75.
229. J Dingle, GF Badger and WS Jordan Jr (1964) Illness in the Home: A Study of 25,000 Illnesses in a Group of Cleveland Families Cleveland, OH: The Press of Western Reserve University
230. AH Van den Biggelaar, R van Ree, LV Rodrigues, et al. (2000) Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 356 1723-1727.
231. T Kemp, N Pearce, P Fitzharris, et al. (1997) Is infant immunization a risk factor for childhood asthma or allergy? Epidemiology 8 678-680.
232. L Nilsson, NI Kjellman and B Bjorksten (1998) A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Arch Pediatr Adolesc Med 152 734-738.
233. J Henderson, K North, M Griffiths, et al. (1999) Pertussis vaccination and wheezing illnesses in young children: prospective cohort study. The Longitudinal Study of Pregnancy and Childhood Team. BMJ 318 1173-1176.
234. JP Mullooly, J Pearson, L Drew, et al. (2002) Wheezing lower respiratory disease and vaccination of full-term infants. Pharmacoepidemiol Drug Saf 11 21-30.
235. F DeStefano, D Gu, P Kramarz, et al. (2002) Childhood vaccinations and risk of asthma. Pediatr Infect Dis J 21 498-504.
236. M Paunio, OP Heinonen, M Virtanen, et al. (2000) Measles history and atopic diseases: a population-based cross-sectional study. JAMA 283 343-346.
237. CL Park and A Frank (1998) Does influenza vaccination exacerbate asthma? Drug Saf 19 83-88.
238. P Kramarz, F DeStefano, PM Gargiullo, et al. (2000) Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team. Arch Fam Med 9 617-623.
239. P Kramarz, F DeStefano, PM Gargiullo, et al. (2001) Does influenza vaccination prevent asthma exacerbations in children? J Pediatr 138 306-310.
240. MA Spence (2001) The genetics of autism. Curr Opin Pediatr 13 561-565.
241. KB Nelson, JK Grether, LA Croen, et al. (2001) Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 49 597-606.
242. AJ Wakefield, SH Murch, A Anthony, et al. (1998) Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351 637-641.
243. Public Health Laboratory Service (2002) Measles outbreak in London. Commun Dis Rep CDR Wkly 12 1.
244. RT Chen and F De Stefano (1968) Vaccine adverse events: causal of coincidental? Lancet 351 611-612.
245. B Taylor, E Miller, CP Farrington, et al. (1999) Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 353 2026-2029.
246. CP Farrington, E Miller and B Taylor (2001) MMR and autism: further evidence against a causal association. Vaccine 19 3632-3635.
247. RL Davis, P Kramarz, K Bohlke, et al. (2001) Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med 155 354-359.
248. JA Kaye, M Mar Melero-Montes and H Jick (2001) Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 322 460-463.
249. L Dales, SJ Hammer and NJ Smith (2001) Time trends in autism and in MMR immunization coverage in California. JAMA 285 1183-1185.
250. E Fombonne and S Chakrabarti (2001) No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 108 E58.
251. B Taylor, E Miller, R Lingam, et al. (2002) Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 324 393-396.
252. H Honda, Y Shimizu and M Rutter (2005) No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatr Allied Discip 46 572-579.
253. KM Madsen and M Vestergaard (2004) MMR vaccination and autism: what is the evidence for a causal association? Drug Safety 27 831-840.
254. F DeStefano and WW Thompson (2004) MMR vaccine and autism: an update of the scientific evidence. Exp Rev Vacc 3 19-22.
255. F DeStefano, TK Bhasin, WW Thompson, et al. (2004) Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 113 259-266.
256. K Wilson, E Mills, C Ross, et al. (2003) Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adol Med 157 628-634.
257. E Miller (2003) Measles-mumps-rubella vaccine and the development of autism. Sem Pediatr Infect Dis 14 199-206.
258. K Stratton, A Gable and PMM Shetty (2001) Measles-mumps-rubella vaccine and autism. Institute of Medicine, Immunization Safety Review Committee. Immunization Safety Review Washington, DC: National Academy Press
259. Centers for Disease Control and Prevention (1999) Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 48 563-565.
260. Centers for Disease Control and Prevention (1999) Recommendations regarding the use of vaccines that contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 48 996-998.
261. D. Marsh Do, TW Clarkson, C Cox, et al. (1987) Fetal methylmercury poisoning: relationship between concentration in single strands of maternal hair and child effects. Arch Neurol 44 1017-1022.
262. A Hviid, et al. (2003) Association between thimerosal containing vaccine and autism. JAMA 290 1763-1766.
263. T Verstraeten, et al. (2003) Safety of thimerosal containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 112 1039-1048.
264. J Heron and J Golding ALSPAC Study Team (2004) Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not show a causal association. Pediatrics 114 577-583.
265. N Andrews, et al. (2004) Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not show a causal association. Pediatrics 114 584-591.
266. E Fombonne, R Zakarian, A Bennett, et al. (2006) Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunization. Pediatrics 118 139-150.
267. SK Parker, B Schwartz, J Todd and LK Pickering (2004) Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 114 793-804.
268. D Stratton, A Gable and MC McCormick (Eds) (2001) Institute of Medicine Immunization Safety Review: Thimerosal-containing Vaccines and Neurodevelopmental Disorders Washington, DC: National Academy Press
269. KB Nelson and ML Bauman (2003) Thimerosal and autism? Pediatrics 111 64-679.
270. C Gundacker, B Pietschnig, KJ Wittmann, et al. (2002) Lead and mercury in breast milk. Pediatrics 110 873-878.
271. SJ Clark, MD Cabana, T Malik, et al. (2001) Hepatitis B vaccination practices in hospital newborn nurseries before and after changes in vaccination recommendations. Arch Pediatr Adolesc Med 155 915-920.
272. P Davies, S Chapman and J Leask (2002) Antivaccination activists on the World Wide Web. Arch Dis Child 87 22-25.
273. RM Wolfe, LK Sharp and MS Lipsky (2002) Content and design attributes of antivaccination web sites. JAMA 287 3245-3248.
274. GL Freed, SL Katz and SJ Clark (1996) Safety of vaccinations: Miss America, the media, and public health. JAMA 276 1869-1872.
275. JA Leask and S Chapman (1998) An attempt to swindle nature: press anti-immunisation reportage 1993–1997. Aust N Z J Public Health 22 17-26.
276. BG Gellin, EW Maibach and EK Marcuse (2000) Do parents understand immunizations? A national telephone survey. Pediatrics 106 1097-1102.
277. National Research Council (1989) Improving Risk Communication Washington, DC: National Academy Press
278. A Bostrom (1997) Vaccine risk communication: lessons from risk perception, decision making and environmental risk communication research. Risk Health Saf Environment 8 173-200.
279. B Fischhoff, S Watson and C Hope (1990) Defining risk. T Glickman, M Gough (Eds) Readings in Risk Washington, DC: Resources for the Future 30-41.
280. P Slovic (2001) The risk game. J Haz Materials 86 17-24.
281. P Slovic (1987) Perception of risk. Science 236 280-285.
282. J Adams (1995) Risk London: University College London Press
283. C Forrest and R Hix Mays (1997) The Practical Guide to Environmental Community Relations New York: John Wiley
284. O Renn and D Levine (1991) Credibility and trust in risk communications. R Kasperson, P Stallen (Eds) Communicating Risk to the Public: International Perspectives Dordrecht, The Netherlands: Kluwer Academic
285. P Bennett (1999) Understanding responses to risk: some basic findings. P Bennett, K Calman (Eds) Risk Communication and Public Health New York: Oxford University Press 3-19.
286. D Holtgrave, B Tinsley and L Kay (1995) Encouraging risk reduction: a decision-making approach to message design. E Maibach, R Parrott (Eds) Designing Health Messages Thousand Oaks, CA: Sage 24-40.
287. DA Asch, J Baron, JC Hershey, et al. (1994) Omission bias and pertussis vaccination. Med Decis Making 14 118-123.
288. RJ Donovan and G Jalleh (2000) Positive versus negative framing of a hypothetical infant immunization: the influence of involvement. Health Educ Behav 27 82-95.
289. AM O'Connor, RA Pennie and RE Dales (1996) Framing effects on expectations, decisions, and side effects experienced: the case of influenza immunization. J Clin Epidemiol 49 1271-1276.
290. FM Lynn and GJ Busenberg (1995) Citizen advisory committees and environmental policy: what we know, what's left to discover. Risk Anal 15 147-162.
291. A Goldman (1995) The refutation of medical paternalism. JD Arras, B Steinbock (Eds) Ethical Issues in Modern Medicine Mountain View, CA: Mafield 58-66.
292. KM Severyn (1996) Jacobson v. Massachusetts: impact on informed consent and vaccine policy. J Pharm Law 5 249-274.
293. JC Hershey, DA Ash, T Thumasathit, et al. (1994) The role of altruism, free riding, and bandwagoning in vaccination decisions. Organ Behav Hum Decis Process 59 177-187.
294. DA Salmon, M Haber, EJ Gangarosa, et al. (1999) Health consequences of religions and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA 282 47-53.
295. DR Feikin, DC Lezotte, RF Hamman, et al. (2000) Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 284 3145-3150.
296. DA Salmon and AW Siegel (2001) Religious and philosophical exemptions from vaccination requirements and lessons learned from conscientious objectors and conscription. Public Health Rep 116 289-295.
297. JS Rota, DA Salmon, LE Rodewald, et al. (2001) Processes for obtaining nonmedical exemptions to state immunization laws. Am J Public Health 91 645-648.
298. World Health Organization (1997) Surveillance of adverse events following immunization (WHO/EPI/TRAM/93.02 Rev. 1) Geneva: World Health Organization
299. TJ Safranek, DN Lawrence, LT Kurland, et al. (1991) Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976–1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 133 940-951.
300. Fine PEM, Sterne J. High titer measles vaccine before nine months of age: implications for child survival [working paper no. 13, 1992]. Presented at Consultation on Studies Involving High Titer Measles Vaccines Before Nine Months of Age, Atlanta, GA, June 16–17, 1992.
301. NA Halsey (2002) Anthrax vaccine and causality assessment from individual case reports. Pharmacoepidemiol Drug Saf (3), 185-187. discussion 203–204
302. Betraying the public over nvCJD risk [editorial]. Lancet 348 1529.
303. HL Coulter and BL Fisher (1991) DTP: A Shot in the Dark Garden City Park, New York: Avery
304. D McNamee (1997) Communicating drug-safety information. Lancet 350 1646.
305. T Wilkie (1996) Sources in science: who can we trust? Lancet 347 1308-1311.
306. J Monahan (1995) Using positive affect when designing health messages. E Maibach, R Parrott (Eds) Designing Health Messages Thousand Oaks, CA: Sage 81-98.
307. AR Hinman and WA Orenstein (1994) Public health considerations. SA Plotkin, EA Mortimer (Eds) Vaccines 2nd ed. Philadelphia: WB Saunders 930-932.
308. National Childhood Vaccine Injury Act of 1986, Section 2125, Public Health Service Act, 42 USC § 300aa (Supp 1987).
309. EW Clayton, GB Hickson and CS Miller (1994) Parents’ responses to vaccine information pamphlets. Pediatrics 93 369-372.
310. JA Bocchini Jr, TC Davis, D Fredrickson, et al. (1996) Parent comprehension of polio vaccine information pamphlets. Pediatrics 97 804-810.
311. TC Davis, DD Fredrickson, C Arnold, et al. (1998) A polio immunization pamphlet with increased appeal and simplified language does not improve comprehension to an acceptable level. Patient Educ Counsel 33 25-37.
312. TC Davis, DD Fredrickson, CL Arnold, et al. (2001) Childhood vaccine risk/benefit communication in private practice office settings: a national survey. Pediatrics 107 E17.
313. TC Davis, DD Fredrickson, C Bocchini, et al. (2002) Improving vaccine risk/benefit communication with an immunization education package: a pilot study. Ambul Pediatr 2 193-200.
314. DH Shawn and R Gold (1987) Survey of parents’ attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ 136 1038-1040.
315. R Weitkunat, A Markuzzi, S Vogel, et al. (1998) Psychological factors associated with the uptake of measles immunization. J Health Psychol 3 273-284.
316. J Benbassat, D Pilpel and M Tidhar (1998) Patient's preferences for participation in clinical decision making: A review of published surveys. Behavioral Medicine 24 81-88.
317. T Pickering, L Clemow, K Davidson and W Gerin (2003) Behavioral cardiology—has its time finally arrived. Mt. Sinai J Med 70 101-112.
318. L Ball, G Evans and A Bostrom (1998) Risky business: challenges in vaccine risk communication. Pediatrics 101 453-458.
319. DA Gust, A Kennedy, I Shui, et al. (2005) Parent attitudes toward immunizations and healthcare providers: The role of information. Am J Prevent Med 29 105-112.
320. S Ryan, A Hassell, P Dawes and S Kendall (2003) Control perceptions in patients with rheumatoid arthritis: the impact of the medical consultation. Rheumatology (Oxford) 42 135-140.
321. U Manjunath and RP Pareek (2003) Maternal knowledge and perceptions about the routine immunization programme–a study in a semiurban area in Rajasthan. Indian J Med Sci 57 158-163.
322. DA Gust, C Brown, K Sheedy, et al. (2005) Immunization attitudes and beliefs among parents: Beyond a dichotomous perspective. American Journal of Health Behavior 29 81-92.
323. TC Davis, DD Fredrickson, CL Arnold, Cross, et al. (2001) Childhood vaccine risk/benefit communication in private practice office settings: a national survey. Pediatrics 107 E17.
324. TA Lieu, SB Black, P Ray, et al. (1994) Risk factors for delayed immunization among children in an HMO. Am J Public Health 84 1621-1625.
325. EW Clayton, GB Hickson and CS Miller (1994) Parents’ responses to vaccine information pamphlets. Pediatrics 93 369-372.
326. I Shui, I Kennedy, K Wooten, et al. (2005) Factors Influencing African American Mothers’ Concerns about Immunization Safety: A Summary of Focus Group Findings in Atlanta. J National Med Assoc 97 657-666.
327. C Lannon, V Brack, J Stuart, et al. (1995) What mothers say about why poor children fall behind on immunizations: a summary of focus groups in North Carolina. Arch Pediatr Adolesc. Med 149 1070-1075.
328. D Evers (2001) Teaching mothers about childhood immunizations. MCN Am J Matern Child Nurs 26 253-256.
329. RC Kessler, RB Davis, DF Foster, et al. (2001) Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 135 262-268.
330. KR Pelletier, JA Astin and WL Haskell (1999) Current trends in the integration and reimbursement of complementary and alternative medicine by managed care organizations (MCOs) and insurance providers: 1998 update and cohort analysis. Am J Health Promot 14 125-133.
331. PM Barnes, E Powell-Griner, K McFann and RL Nahin (2004) Complementary and alternative medicine use among adults: United States, 2002. Adv. Data 1-19.
332. JB Campbell, JW Busse and HS Injeyan (2000) Chiropractors and vaccination: A historical perspective. Pediatrics 105 E43.
333. R Anderson (1990) Chiropractors for and against vaccines. Med. Anthropol 12 169-186.
334. DA Salmon, LH Moulton, SB Omer, et al. (2005) Factors associated with refusal of childhood vaccines among parents of school-aged children: a case-control study. Arch Pediatr Adolesc Med 159 470-476.
335. JR Meszaros, DA Asch, J Baron, et al. (1996) Cognitive processes and the decisions of some parents to forego pertussis vaccination for their children. J Clin Epidemiol 49 697-703.
336. DA Salmon, LH Moulton and SB Omer (2005) Factors associated with refusal of childhood vaccines among parents of school-aged children: a case-control study. Arch Pediatr Adolesc. Med 159 470-476.
337. Gust DA, Campbell S, Kennedy A, et al. Association between parental concerns and medical-seeking behavior after immunization. Am J Prevent Med [in press].
338. MF Fleming, MP Mundt, MT French, et al. (2000) Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. Med Care 38 7-18.
339. W Levinson, DL Roter, JP Mullooly, et al. (1997) Physician-patient communication. The relationship with malpractice claims among primary care physicians and surgeons. JAMA 277 553-559.
340. P Slovic (1999) Trust, emotion, sex, politics, and science: Surveying the risk-assessment battlefield. Risk Analysis 19 689-701.
341. VT Covello, RG Peters, JG Wojtecki and RC Hyde (2001) Risk communication, the West Nile virus epidemic, and bioterrorism: responding to the communication challenges posed by the intentional or unintentional release of a pathogen in an urban setting. J Urban Health 78 382-391.
342. RT Chen, G Mootrey and F DeStefano (2000) Safety of routine childhood vaccinations: an epidemiological review. Paediatr Drugs 2 273-290.
343. A Fisher (1991) Risk communication challenges. Risk Analysis 11 173-179.
344. BB Johnson (1999) Risk comparisons in a democratic society: What people say they do and do not want. Risk: Health, Safety and Environment 10 221-230.
345. PM Sandman, ND Weinstein and P Miller (1994) High risk or low: how location on a ‘risk ladder’ affects perceived risk. Risk Analysis 14 35-45.
346. IM Lipkus and JG Hollands (1999) The visual communication of risk. J Natl Cancer Inst Monogr 149-163.
347. DB McCallum, SL Hammond and VT Covello (1991) Communicating about environmental risks: how the public uses and perceives information sources. Health Education Quarterly 18 349-361.
348. RM Kaplan, B Hammel and LE Schimmel (1986) Patient information processing and the decision to accept treatment. J Soc Behav Personality 1 113-120.
349. JD Miller and LG Kimmel (2001) Biomedical communication: purposes, audience, and strategies New York: Academic Press
350. WA Orenstein, W Atkinson, D Mason, et al. (1990) Barriers to vaccinating preschool children. J Health Care Poor Underserved 1 315-330.
351. N Raithatha, R Holland, S Gerrard and I Harvey (2003) A qualitative investigation of vaccine risk perception amongst parents who immunize their children: a matter of public health concern. J Public Health Med 25 161-164.
352. A Kennedy and D Gust (2005) Parental vaccine beliefs and child's school type. J School Health 75 276-280.
353. DS Diekema (2005) Responding to parental refusals of immunization of children. Pediatrics 115 1428-1431.
354. Association of American Medical Colleges (1999) Contemporary Issues in Medicine: Communication in Medicine: Report III of the Medical School Objectives Project Washington, DC: AAMC
355. TR Egnew, LB Mauksch, T Greer and SJ Farber (2004) Integrating communication training into a required family medicine clerkship. Acad. Med 79 737-743.
356. FG Soto Mas, RL Papenfuss, HE Jacobson, et al. (2005) Hispanic physicians’ tobacco intervention practices: a cross-sectional survey study. BMC Public Health 5 120.
357. SJ Ackerman, SB Duff, PH Dennehy, et al. (2001) Economic impact of an infection control education program in a specialized preschool setting. Pediatrics 108 E102.
358. CL Discher, D Klein, L Pierce, et al. (2003) Heart failure disease management: impact on hospital care, length of stay, and reimbursement. Congest Heart Fail 9 77-83.
359. GA Poland, D Murray and R Bonilla-Guerrero (2002) New vaccine development. BMJ 324 1315-1319.
360. S Russo, L Turin, A Zanella, et al. (1997) What's going on in vaccine technology? Med Res Rev 17 277-301.
361. BJ Ward (2000) Vaccine adverse events in the new millennium: is there reason for concern? Bull World Health Organ 78 205-215.
362. Vaccine Supply and quality surveillance of adverse events following immunization. Wkly Epidemiol Rec 71 237-242.
363. JM Olive, JB Risi Jr and CA de Quadros (1997) National immunization days: experience in Latin America. J Infect Dis 175(Suppl 1), S189-S193.
364. L Simonsen, A Kane, J Lloyd, et al. (1999) Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 77 789-800.
365. DU Ekwueme, BG Weniger and RT Chen (2002) Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull World Health Organ 80 859-870.
366. B Melgaard, V Li-Frankenstein, S Rasheed, et al. (1999) WHO-UNICEF-UNFPA joint statement on the use of auto-disable syringes in immunization services Geneva: World Health Organization, Division of Vaccine and Biologicals
367. J Lloyd (2000) Technologies for Vaccine Delivery in the 21st Century (WHO/V&B/00.35) Geneva: World Health Organization, Division of Vaccines and Biologicals
368. National Transportation Safety Board (1998) We are all safer: NTSB-inspired improvements in transportation safety Washington DC: NTSB
369. RA Merrill (1997) Food safety regulation: reforming the Delaney Clause. Annu Rev Public Health 18 313-340.
370. LB Leveton, HC Sox and MA Stoto (Eds) (1995) HIV and the Blood Supply: An Analysis of Crisis Decisionmaking Washington, DC: National Academy Press
371. Chen RT. A multi-faceted approach to improve vaccine safety in the United States. In Proceedings of the 24th National Immunization Conference, Orlando, FL, May 21–25, 1990. Atlanta, Centers for Disease Control, Division of Immunization, 1990, pp 107–109.
372. P Barach and SD Small (2000) Reporting and preventing medical mishaps: lessons from non-medical near miss reporting systems. BMJ 320 759-763.
373. JF Cordero, FA Guerra, KN Saarlas, et al. (1997) Developing national immunization registries: experience from the All Kids Count Program. Am J Prev Med 3 1-128.
374. MJ Khoury (1997) Genetic epidemiology and the future of disease prevention and public health. Epidemiol Rev 19 175-180.
375. G Francois, M Kew, P VanDamme, et al. (2001) Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine 19 3799-3815.
376. Centers for Disease Control and Prevention (1999) Achievements in public health, 1900–1999: impact of vaccines universally recommended for children-United States, 1990–1998. MMWR Morb Mortal Wkly Rep 48 243-248.